Navigation Links
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Date:1/3/2008

DEERFIELD, Ill., Jan. 3 /PRNewswire/ -- Takeda Pharmaceutical Company Limited (Takeda) announced today that Takeda Global Research & Development Center, Inc. submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for alogliptin (development code: SYR-322), a highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor under investigation for the treatment of type 2 diabetes. Discovered by Takeda San Diego, Inc., alogliptin was designed to selectively inhibit DPP-4 taken orally once daily.

DPP-4 inhibitors are a new class of oral agents for the treatment of type 2 diabetes, which slow the inactivation of incretin hormones GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). The incretins play a major role in regulating blood glucose levels and may have the potential to improve pancreatic beta-cell function.

The NDA submission was supported by six Phase 3 clinical trials involving over 2,000 patients conducted in 220 centers worldwide. The safety and efficacy of alogliptin was studied as a once-daily monotherapy adjunct to diet and exercise and as an add-on therapy to other antidiabetic medications including sulfonylureas, metformin, thiazolidinediones (TZDs), and insulin. In the studies, alogliptin was associated with statistically significant reductions in hemoglobin A1c, which reflects average blood glucose concentration over the previous two to three months. Alogliptin was generally well-tolerated and weight neutral. There was no increase in hypoglycemia compared to placebo.

"The NDA submission for alogliptin is a significant milestone for Takeda, as it has the potential to position us as one of the global leaders in diabetes treatment," said Yasuchika Hasegawa, president of Takeda. "Takeda's continued growth, now and in the future, will be based on our ability to focus and have success in this therapeutic area. Our hope is that alogliptin will become an important treat
'/>"/>

SOURCE Takeda Global Research & Development Center, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Peregrine Pharmaceuticals Submits Clinical Protocol to Initiate Bavituximab Phase II Trial in Patients With Metastatic Breast Cancer
3. Vanda Pharmaceuticals Submits Iloperidone New Drug Application
4. Peregrine Pharmaceuticals Submits Clinical Protocol for New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer
5. Roche Submits Application for FDA Approval of ACTEMRA(R) for the Treatment of Rheumatoid Arthritis
6. AstraZeneca Submits sNDAs for SEROQUEL XR(TM) for the Treatment of Bipolar Mania and Bipolar Depression
7. ORENCIA(R) (abatacept) Supplemental Biologics License Application for Juvenile Idiopathic Arthritis Accepted by FDA for Filing and Review
8. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
9. Indevus Announces Submission of New Drug Application
10. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
11. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... LONDON , July 7, 2015 ... Sales Forecasts, Helping Your Influence  ,Are ... ? If so, now gain technological and commercial predictions ... authority. There explore trends in research and development, results, ... by visiongain shows you what,s possible for ...
(Date:7/7/2015)... , July 7, 2015  PAREXEL International Corporation (NASDAQ: ... and Fiscal Year 2015 on Wednesday, August 5 th , ... will be available on PAREXEL,s website at www.PAREXEL.com ... PAREXEL will host a conference call and live webcast ... 2015 to discuss the results.  To access the webcast, visit ...
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
Breaking Medicine Technology:Biobanking for Medicine: Technology, Industry and Market 2015-2025 2Biobanking for Medicine: Technology, Industry and Market 2015-2025 3Biobanking for Medicine: Technology, Industry and Market 2015-2025 4Biobanking for Medicine: Technology, Industry and Market 2015-2025 5Biobanking for Medicine: Technology, Industry and Market 2015-2025 6Biobanking for Medicine: Technology, Industry and Market 2015-2025 7Biobanking for Medicine: Technology, Industry and Market 2015-2025 8Biobanking for Medicine: Technology, Industry and Market 2015-2025 9Biobanking for Medicine: Technology, Industry and Market 2015-2025 10PAREXEL International Announces Date Of Fourth Quarter And Fiscal Year 2015 Earnings Release And Conference Call 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4
... 13, 2010 Endologix, Inc. (Nasdaq: ELGX ... announced today that it has completed the acquisition of ... for the treatment of Abdominal Aortic Aneurysms (AAAs) that ... aneurysm repair (EVAR) devices and expand the global AAA ...
... Dec. 13, 2010 Bionovo, Inc. (Nasdaq: BNVI ... of innovative treatments for women,s health and cancer, today announced ... and Drug Administration,s (FDA) Clinical Guidance meeting that took place ... with the Company,s proposed overall clinical development plan. ...
Cached Medicine Technology:Endologix Completes Acquisition of Nellix 2Endologix Completes Acquisition of Nellix 3Endologix Completes Acquisition of Nellix 4Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 2Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 3Bionovo Releases FDA-Approved Clinical Development Plan for Menerba 4
(Date:7/7/2015)... Madison Wisconsin (PRWEB) , ... July 07, 2015 , ... ... 2015 Best of Madison winners in the home service category. This honor can only ... popularity is growing because of the safety of the products and methods they use ...
(Date:7/7/2015)... ... 2015 , ... Difass USA, a modern supplement brand committed to excellence, understands ... work is knowing that there is hopefully a vacation to look forward to this ... Planning for a vacation can be quite stressful, and it’s difficult sometimes to fully ...
(Date:7/7/2015)... , ... July 07, 2015 , ... ... highlights rumors about possible facial rejuvenation that have emerged about Hillary Clinton. Two ... Secretary of State looks more youthful than she has in some time and ...
(Date:7/7/2015)... York, NY (PRWEB) , ... July 07, 2015 , ... ... the email newsletter and website that helps active people find the most fun activities ... and active lifestyle coverage for millennials. It also increases Greatist’s opportunity for events, e-commerce, ...
(Date:7/7/2015)... ... July 07, 2015 , ... Illinois cannabis cultivation centers and ... permit holders. The Medical Cannabis Alliance of Illinois’ (MCAI) board and its members ... committed to making sure patients have access to cannabis as a viable medical ...
Breaking Medicine News(10 mins):Health News:Environmentally-Friendly House Cleaning Company Wins Best of Madison Magazine Award 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 2Health News:Difass USA Offers Eight Tips to Help Relax and Enjoy Summer Vacation 3Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 2Health News:Recent Article on Hillary Clinton Plastic Surgery Speculation Illuminates the Reasons Many Professionals Explore Facial Rejuvenation, says Dr. J 3Health News:Greatist Acquires Active Lifestyle Brand Blood, Sweat & Cheers 2Health News:Cannabis Growers and Dispensaries Form Medical Cannabis Alliance of Illinois 2
... S.C., Nov. 12 What does a,thirty-nine foot Airstream ... cancer? For more than 800 midlands, men last month, ... risk for the disease. The Drive Against Prostate ... for prostate cancer. Doctors Care and WIS-TV,sponsored The Drive ...
... DALLAS, Nov. 12 Hurley Medical Center, a ... physician referral and,class registration services so they will ... a day, seven days a week. The medical ... healthcare-exclusive customer,interaction center, as its partner to provide ...
... Nov. 12 /Xinhua-PRNewswire-FirstCall/ -- China Pharma,Holdings, Inc. ("China Pharma") ... host a conference call at 11:00 a.m. EST on ... quarter of 2007. Joining Ms. Zhilin Li, President ... Chief Financial Officer. The Company plans to release its,earnings ...
... might keep participants from trials , , MONDAY, Nov. 12 (HealthDay ... trial may have placed participants at higher risk of infection ... the case remains unclear. , What is clear ... would-be trial participants away from future AIDS vaccine studies. , ...
... ), the most advanced method of massage,aromatherapy and ... retained one of Florida,s fastest growing PR firms, ... experience on,the planet. "We see the SpaCapsule(R) ... matter,of minutes can take you from planet stress ...
... the Nation,s Premier Centers for Medical ... Education will Host, Live call-in format will ... Nov. 12 SIRIUS Satellite Radio,(Nasdaq: SIRI ) ... Radio Powered by NYU Medical Center," an exclusive, pioneering,24/7 ...
Cached Medicine News:Health News:UCI Medical Affiliates, Inc. Sponsors Doctors Care Record-breaking Drive Against Prostate Cancer 2Health News:Hurley Medical Center Enhances Customer Service Capabilities With Beryl Partnership 2Health News:China Pharma Holdings, Inc. Announces Conference Call to Discuss Third Quarter 2007 Results 2Health News:Fallout From Failed AIDS Vaccine Could Dampen Research 2Health News:Fallout From Failed AIDS Vaccine Could Dampen Research 3Health News:Fallout From Failed AIDS Vaccine Could Dampen Research 4Health News:The Ultimate Stress Reliever, SpaCapsule(R), the Capsule that Takes You on a Rejuvenating Journey to the Spa, Retains TransMedia Group for Soothing PR 2Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 2Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 3Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 4Health News:SIRIUS Satellite Radio to Launch 'Doctor Radio,' a Groundbreaking, 24/7 Health and Wellness Channel, in Partnership With NYU Medical Center 5
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: